Ac immune extends research collaboration with university of pennsylvania focusing on the pathogenic protein tdp-43, a major driver of neurodegenerative diseases

Lausanne, switzerland, nov. 04, 2021 (globe newswire) -- ac immune sa (nasdaq: aciu), a swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it is extending its research partnership with leading scientists at the center for neurodegenerative disease research at the perelman school of medicine at the university of pennsylvania (penn). the partnership is focused on studying the pathological mechanism of transactive response dna binding protein 43 kda (tdp-43) misfolding, aggregation and cell-to-cell transmission.
ACIU Ratings Summary
ACIU Quant Ranking